Selective, Orally Active 5-HT1D Receptor Agonists as Potential Antimigraine Agents
- 1 October 1997
- journal article
- letter
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 40 (22), 3501-3503
- https://doi.org/10.1021/jm9704560
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Inhibition of the Trigemino-Vascular System with 5-HT1D Agonist Drugs: Selectively Targeting Additional Sites of ActionEuropean Neurology, 1996
- The activity of 5-HT1D receptor ligands at cloned human 5-HT1Dα and 5-HT1Dβ receptorsEuropean Journal of Pharmacology, 1995
- A comparison of the contractile effects of 5‐hydroxytryptamine, sumatriptan and MK‐462 on human coronary artery in vitro.British Journal of Clinical Pharmacology, 1995
- Neurogenic Model of MigraineCephalalgia, 1995
- Classification and nomenclature of somatostatin receptorsTrends in Pharmacological Sciences, 1995
- Adverse reactions attributed to sumatriptanEuropean Journal of Clinical Pharmacology, 1994
- Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.Proceedings of the National Academy of Sciences, 1993